Juvaris BioTherapeutics Completes Second Close on $25M Series B Financing

Published On January 27, 2010 |
Juvaris BioTherapeutics, Inc., a Burlingame, CA-based biotechnology company developing adjuvanted vaccines for infectious diseases, has completed a second close on its Series B equity financing of up to $25m.
The additional equity investment came from an undisclosed strategic corporate investor who joins SV Life Sciences and Kleiner Perkins Caufield & Byers in the round.
The funds will be used to advance Juvaris’ novel adjuvant platform of cationic-lipid DNA complexes, which are designed to significantly improve the quality and quantity of immune responses achievable with vaccines, along with the company’s proprietary adjuvanted vaccine pipeline.

Like this Article? Share it!

Leave a Reply